anti-FAP alpha CAR T cell therapy (Genethon)

N/A

Report date: 2025/01/26 18:47:38

Base Information

Drug Nameanti-FAP alpha CAR T cell therapy (Genethon)
Drug Alias Nameanti-fibroblast activating protein alpha CAR T cell therapy (Genethon)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionFibroblast activation protein alpha modulators
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenethon
China Registration ClassN/A

Develop Information

Active CompaniesGenethon
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A